Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Could Be Pharma's Next Big Buyout Target

3 Explosive Stocks With High Short Interest

The image featured for this article is © Ground Picture / Shutterstock.com

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Viking Therapeutics, Inc. remains a Buy as VK2735 is arguably the leading GLP-1 obesity drug candidate outside of Eli Lilly and Novo Nordisk's pipelines. VKTX's pivotal VANQUISH Phase 3 injectable study is make-or-break, with enrollment progressing and data expected by mid-2027. Strong cash reserves support VKTX's R&D, and a flexible maintenance dosing study could differentiate VK2735 from competitors.

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Viking Therapeutics, Inc. is a clinical-stage biotech focused on metabolic and endocrine therapies, highlighted by its promising VK2735 obesity drug. VKTX's pipeline includes late-stage GLP-1/GIP agonists and NASH treatments, positioning it as a key competitor to Eli Lilly and Novo Nordisk. Speculation of a takeover remains strong, with major pharma companies potentially interested due to VKTX's advanced pipeline and de-risking progress.

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated SAN DIEGO , Oct. 21, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such …

Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?

VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 11:20 AM EDT Company Participants Brian Lian - President, CEO & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2023 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Brian Lian - President and CEO Greg Zante - CFO Stephanie Diaz - Manager of IR Conference Call Participants Joon Lee - Truist Steven Seedhouse - Raymond James Jay Olson - Oppenheimer. Naz Rahman - Maxim Group.

AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

Where Does VKTX Stock Stand After the Obesity Pill Setback?

Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

5 Stocks Poised to DOUBLE Your Money by 2027

Viking Therapeutics Loses 20% in a Month: How to Play the Stock

VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.

Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?

Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and future prospects.

Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study

VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Viking Therapeutics: What's Happening With VKTX Stock?

Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk.

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Justin Zelin, BTIG senior biotech analyst, joins 'The Exchange' to discuss GLP-1's and the share decline for Viking Therapeutics and why he's still bullish the stock.

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

CNBC's Angelica Peebles joins 'Money Movers' to discuss Viking Therapy shares plummeting on new obesity drug data.

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Viking Therapeutics (VKTX) shares cratered nearly 45% Tuesday when the biopharma firm reported study of its experimental weight-loss pill raised concerns about side effects.

Viking Therapeutics shares plunge on weight loss trial tolerability concerns

Viking Therapeutics (NASDAQ:VKTX) shares tumbled 43% on Tuesday following the release of data from its Phase 2a Venture Oral weight loss trial showing strong efficacy but raised tolerability concerns. The study showed that participants taking VK-2735 achieved placebo-adjusted weight losses of approximately 7.5% at 60 mg, 10% at 90 mg, and 11% at 120 mg over 13 weeks.

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite being underwhelming compared to Novo and Lilly's oral GLP-1 drugs, VK2735 remains a top-three candidate in a massive, rapidly growing obesity market. Phase 3 injectable VK2735 data will be more decisive, and the market's expectations for weight loss drugs may need to be reset to more realistic levels.

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

The once-daily pill VK2735 had lower weight-loss results on average compared to Eli Lilly's orforglipron, which was tested over 72 weeks. The highest dose of Eli Lilly's once-daily treatment helped patients lose about 12.4% of their body weight in a late-stage trial, well below analyst expectations of 15%, according to FactSet.

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Shares of Viking Therapeutics fell more than 30% on Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. While the weight loss caused by Viking's pill was roughly comparable to that of other oral drugs, the side effects and discontinuation rates appeared to rattle Wall Street.

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. VKTX released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.